Cipla submits application with USFDA for generic version of asthma drug

PTI New Delhi | Updated on May 18, 2020

Umang Vohra, Cipla MD and Global CEO

Drug major Cipla on Monday said it had submitted an application with the US health regulator for a generic version of GSK’s Advair Diskus, which is used in the treatment of asthma and other respiratory disorders.

The company has submitted an abbreviated new drug application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the US Food and Drug Administration (USFDA), Cipla said in a regulatory filing.

The drug firm had recently announced the successful completion of its phase-3 clinical end-point study for the product in the first attempt, it added.

The product is indicated as a twice-daily prescription medicine to treat asthma in patients aged four years and older.

It is also used in the long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing.

According to IQVIA (IMS Health), Advair Diskus and its generic equivalents had US sales of around USD 2.9 billion for the 12 months ending March 2020.

Cipla MD and Global CEO Umang Vohra said, “This marks a significant milestone and represents our commitment to increasing patient access to complex treatment options in the respiratory space and will also play a major role in our strategy towards building a respiratory franchise in the US.”

Published on May 18, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor